NASDAQ: KRYS · Biotechnology

Krystal Biotech (KRYS) fair value and price range

As of 14 Nov 2026, Faircurve's model values Krystal Biotech (KRYS) at $352.42 a share. The stock last closed at $297.90, which puts the model's fair value 18.3% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

Revalued . Price is the close of 16 Nov 2026. Krystal Biotech, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$352.42midpoint of 2,000 simulations
Last close$297.90NASDAQ: KRYS
Gap to fair value+18.3%fair value against price
Model verdictLow evidence gradeevidence grade: Low

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $362.89 to $352.42 (-2.9%). The model shifted weight between the company's own multiple and its peers': most of the move.

What the model makes of itThe price of $297.90 is 18.3% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What's nextNext report on 16 Feb 2027. Options prices imply a move of about 11% either way over the next month. On the model's Scorecard Leaders list since 2 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give KRYS?

The calibrated range for KRYS over 63 trading days is $261.69 to $341.34. It sits around the last close, and its width comes from the volatility that KRYS's own options imply (39% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $226.67 to $530.38. In 61% of the simulations the fair value came out above the price the model ran on.

$138.62$998.56
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $352.42. Dashed line: the last close, $297.90.

Faircurve Insights · 14 Nov 2026

Krystal Biotech, Inc. (KRYS) is a clinical-stage biotechnology company. It develops redosable gene therapies for severe orphan diseases across the United States.

Faircurve's model valued Krystal Biotech on 14 Nov 2026 at a fair value of $352.42 a share, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $362.89, so the model's fair value moved -2.9%. In the model's own words, the move came from shifting weight between the company's own multiple and its peers': most of the move. The calibrated range over 63 trading days is $268.77 to $348.87, built around the price from the volatility the stock's own options imply. Calibrated weekly against realised prices, using 8,038 past valuations, ranges built this way held the price 60% of the time at this horizon. Faircurve's model grades the evidence behind this valuation as low, so no verdict is shown.

Krystal Biotech scores 79 out of 100 on the model's overall quality score, a composite of six factors scored against comparable companies. Profitability scores 100, with ROIC of 20.2% against a peer median of -31.8%. The balance sheet scores 100, with net debt to EBITDA of -1.80x. Stability scores 15, with five-year EBITDA margin downside volatility of 87.0 pts against a peer median of 32.7 pts. The model compares the company with Protagonist Therapeutics, Inc. (PTGX), TG Therapeutics, Inc. (TGTX), BioMarin Pharmaceutical Inc. (BMRN) and Bio-Techne Corporation (TECH).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does KRYS report earnings, and how has the stock reacted?

Krystal Biotech's next earnings report is scheduled for 16 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 9.1% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. KRYS's 30 day implied volatility works out to about 11.3% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across KRYS's last 8 reports, ignoring direction, was 5.9%.

0%5%10%15%20%13.9%1.1%4 Nov '2411.1%16.5%19 Feb '2511.4%12.5%4 Aug '2512.7%2.9%3 Nov '259.8%2.5%17 Feb '2610.3%7.0%4 May '2613.0%4.8%3 Aug '2610.6%8.2%2 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in KRYS

5%10%15%20%25%2 Nov '26 report3 Aug '26 report4 May '26 report17 Feb '26 report11% at 16 Nov '2626 Dec '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 12% on 26 Dec 2025, reached 20% on 31 Jul 2026 and reads 11% on 16 Nov 2026. The marks are report dates.

How does KRYS score on business quality?

Krystal Biotech's overall quality score is 79 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.10020.2%ROIC-31.8%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).801.38xFCF / net income
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.7033.9%Revenue growth, trailing33.9%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.760.2%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.100-1.80xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.1587.0 ptsEBITDA margin downside volatility, 5y32.7 pts

How does KRYS compare with similar companies?

The companies in biotechnology closest to Krystal Biotech in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
PTGX Protagonist Therapeutics, Inc.$124.83$104.97-15.9%Overvalued
TGTX TG Therapeutics, Inc.$62.76$75.36+20.1%Undervalued
CYTK Cytokinetics, Incorporated$53.17$63.03+18.5%Low evidence grade
BMRN BioMarin Pharmaceutical Inc.$57.99$69.09+19.1%Undervalued
HALO Halozyme Therapeutics, Inc.$96.50$111.93+16.0%Low evidence grade
TECH Bio-Techne Corporation$72.79$65.76-9.7%Fairly valued
ARWR Arrowhead Pharmaceuticals, Inc.$44.21$53.67+21.4%Low evidence grade
LGND Ligand Pharmaceuticals Incorporated$301.71$282.99-6.2%Low evidence grade

What the comparable companies' multiples alone would give for KRYS, the peer-implied price, is $609.69 a share on this run. The fair value weighs that against the company's own multiple.

All biotechnology stocks ranked by gap to fair value

Krystal Biotech at a glance

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States.

Market value
$9.0B
Sector
Healthcare
Industry
Biotechnology
Revenue expected, next twelve months
$628M
Consensus revenue growth, next fiscal year
+27.9%
Analysts with estimates
8
Beta to the US market
0.61
First valued by Faircurve
11 Jul 2026

How the fair value is worked out: the model prices Krystal Biotech on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for KRYS was $362.89. As of 14 Nov 2026 it is $352.42, a change of -2.9%. The model shifted weight between the company's own multiple and its peers': most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Krystal Biotech's valuation

Is Krystal Biotech stock undervalued or overvalued?

Faircurve's model puts KRYS's fair value at $352.42 a share against a last close of $297.90, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What is KRYS's fair value?

$352.42 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $226.67 to $530.38.

What price range does the model give KRYS?

$261.69 to $341.34 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Krystal Biotech report earnings next?

The next report is scheduled for 16 Feb 2027. Companies can move their dates.

How much has KRYS moved on past earnings reports?

Across its last 8 reports the median two session move was 5.9%, ignoring direction. The largest was +16.5% around the report of 19 Feb 2025.

How confident is the model in this valuation?

The model's evidence grade for KRYS is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on KRYS

The model has an idea open on KRYS under Scorecard Leaders since 2 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on KRYS with their outcomes. A free account is enough.

Keep reading